Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
This map shows the geographic impact of S B Howell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S B Howell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S B Howell more than expected).
This network shows the impact of papers produced by S B Howell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S B Howell. The network helps show where S B Howell may publish in the future.
Co-authorship network of co-authors of S B Howell
This figure shows the co-authorship network connecting the top 25 collaborators of S B Howell.
A scholar is included among the top collaborators of S B Howell based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with S B Howell. S B Howell is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Kerber, Charles W., et al.. (1998). An organ-preserving selective arterial chemotherapy strategy for head and neck cancer.. American Journal of Neuroradiology. 19(5). 935–41.48 indexed citations
Aebi, Stefan, Daniel Fink, Robert T. Gordon, et al.. (1997). Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.. PubMed. 3(10). 1763–7.148 indexed citations
Pietras, Richard J., et al.. (1994). Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.. PubMed. 9(7). 1829–38.362 indexed citations
Andrews, Paul A., et al.. (1987). Methionine does not modulate cisplatin cytotoxicity in human ovarian carcinoma cells. 28. 329.1 indexed citations
14.
Taetle, Raymond, Fred S. Rosen, Ian Abramson, John M. Venditti, & S B Howell. (1987). Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian carcinoma xenografts.. PubMed. 71(3). 297–304.44 indexed citations
15.
Howell, S B, Michael P. Murphy, Julie Johnson, P Wamsley, & Inder M. Verma. (1987). Gene therapy for thioguanine-resistant human leukemia.. PubMed. 4(3). 157–68.3 indexed citations
16.
Howell, S B, et al.. (1986). Effects of calcium, W7, W5 and a phorbol ester on human ovarian carcinoma cell growth. Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States).1 indexed citations
Howell, S B & Sabrina Gill. (1986). Lack of synergy between cisplatin and cytarabine against ovarian carcinoma in vitro.. PubMed. 70(3). 409–10.14 indexed citations
19.
Taetle, Raymond & S B Howell. (1983). Preclinical re-evaluation of benzaldehyde as a chemotherapeutic agent.. PubMed. 67(6). 561–6.11 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.